VivoSeq
Neurology

Muscle Spasticity

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Muscle Spasticity is an early-stage landscape with 1 program across 2 companies. The most active players are Amphastar Pharmaceuticals, Inc., Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Amphastar Pharmaceuticals, Inc.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Hyaluronidase

Amphastar Pharmaceuticals, Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Peripheral Modulation of Muscle Stiffness and Spasticity
Active, not recruiting·JJohns Hopkins University·Phase 2·NCT03306615·56 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)